These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32856157)

  • 1. Mycophenolic acid area under the concentration-time curve is associated with therapeutic response in childhood-onset lupus nephritis.
    Godron-Dubrasquet A; Woillard JB; Decramer S; Fila M; Guigonis V; Tellier S; Morin D; Sordet M; Saint-Marcoux F; Harambat J
    Pediatr Nephrol; 2021 Feb; 36(2):341-347. PubMed ID: 32856157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM; Reinders ME; den Hartigh J; Huizinga TW; Rabelink AJ; de Fijter JW; Berger SP
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study.
    Zhang L; Chen L; Liu X; Huang Z; Zheng Y; Tang K; Jiang X; Chen P
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI180-SI187. PubMed ID: 38730553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study.
    Alexander S; Fleming DH; Mathew BS; Varughese S; Jeyaseelan V; Tamilarasi V; Jacob CK; John GT
    Ther Drug Monit; 2014 Aug; 36(4):423-32. PubMed ID: 25014074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To TDM or not to TDM in lupus nephritis patients treated with MMF?
    van Gelder T; Berden JH; Berger SP
    Nephrol Dial Transplant; 2015 Apr; 30(4):560-4. PubMed ID: 24811231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring.
    Zabotti A; Baraldo M; Quartuccio L; Sacco S; De Marchi G; De Vita S
    Clin Rheumatol; 2015 Jan; 34(1):171-4. PubMed ID: 25249327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Br J Clin Pharmacol; 2015 Nov; 80(5):1064-75. PubMed ID: 25959850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis.
    Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y
    Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring.
    Łuszczyńska P; Pawiński T; Kunicki PK; Durlik M; Augustyniak-Bartosik H; Hurkacz M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):371-379. PubMed ID: 30430214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients.
    Hui-Yuen JS; Tran T; Taylor J; Truong K; Li X; Bermudez LM; Starr AJ; Eichenfield AH; Imundo LF; Askanase AD
    J Clin Rheumatol; 2016 Mar; 22(2):75-9. PubMed ID: 26906299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
    Sagcal-Gironella AC; Fukuda T; Wiers K; Cox S; Nelson S; Dina B; Sherwin CM; Klein-Gitelman MS; Vinks AA; Brunner HI
    Semin Arthritis Rheum; 2011 Feb; 40(4):307-13. PubMed ID: 20655577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
    Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
    Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
    Zahr N; Arnaud L; Marquet P; Haroche J; Costedoat-Chalumeau N; Hulot JS; Funck-Brentano C; Piette JC; Amoura Z
    Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of trough mycophenolic acid levels for the management of lupus nephritis.
    Pourafshar N; Karimi A; Wen X; Sobel E; Pourafshar S; Agrawal N; Segal E; Mohandas R; Segal MS
    Nephrol Dial Transplant; 2019 Jan; 34(1):83-89. PubMed ID: 29548021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.
    Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):993-1004. PubMed ID: 28536776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S; Duffau P; Lazaro E; Chapouly C; Greib C; Viallard JF; Pellegrin JL; Saux MC; Breilh D
    Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis.
    Katsuno T; Ozaki T; Ozeki T; Hachiya A; Kim H; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Mizuno M; Ito Y; Maruyama S
    Clin Exp Nephrol; 2018 Dec; 22(6):1341-1350. PubMed ID: 29796823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of mycophenolic acid and clinical outcomes of lupus nephritis: a systematic review and meta-analysis.
    Wuttiputhanun T; Naiyarakseree N; Udomkarnjananun S; Kittanamongkolchai W; Asada L; Chariyavilaskul P; Townamchai N; Avihingsanon Y
    Lupus Sci Med; 2024 Jan; 11(1):. PubMed ID: 38233072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Drug Monitoring of Mycophenolic Acid in Lupus Nephritis: A Review of Current Literature.
    Łuszczyńska P; Pawiński T
    Ther Drug Monit; 2015 Dec; 37(6):711-7. PubMed ID: 26034895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.